Last reviewed · How we verify

NCT06703853: cfDNA

Identifying Tissue-of-origin in Transplant Patients and Patients with Malignancies.

Active, enrolled Last updated 25 November 2024
What this trial tests

trial in Malignancies in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 August 2024
Primary endpoint
1 November 2027
12 November 2027

Quick facts

Lead sponsorHadassah Medical Organization
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 August 2024
Primary completion1 November 2027
Estimated completion12 November 2027
Sites1 location across Israel

Conditions studied

Sponsor

Hadassah Medical Organization — full company profile →

Who can join

Adults 18 to 80, any sex, with Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the investigators are developing a method for diagnosing cell death in the body using blood and urine tests. The test is based on two well-known phenomena in biology. First, when cells in the body die, short fragments of their DNA, about 150 bases long, find their way into the bloodstream for a short period of time of about fifteen minutes to an hour, before being eliminated in the liver and kidney. The details of this process are not fully known, but it is clear that the phenomenon exists. Already today, this phenomenon is widely used clinically for prenatal diagnosis of chromosomal aberrations in the DNA of the fetus that is found in large quantities in the mother's blood. Liquid biopsies from cancer have already been developed, based on the identification of somatic mutations originating from a cancerous tumor in the free DNA found in the serum or plasma. In the case of cancer, liquid biopsies may be a convenient way to monitor the genetic evolution of the tumor, response to treatments, and more. This approach of detecting cell death using free DNA in the bloodstream has a severe limitation when it comes to the death of cells whose genome is not different from the genome of the other tissues in the body, and therefore the DNA cannot be associated with the tissue of origin based on sequence analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Malignancies

Currently open trials in the same condition.

Other Hadassah Medical Organization trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06703853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing